SAN DIEGO and FORT WAYNE, Ind., Dec. 17, 2015 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, and Cataract & Laser Institute, a leading provider of refractive and cataract surgery, today announced they have entered into a national account agreement to provide Imprimis’ Dropless Cataract Therapy to patients at the Cataract & Laser Institute.
Randal K. Hughes, MD, Drew Davis, MD, Kuumba Long, MD and Stephen Kruse, MD of the Cataract & Laser Institute stated, “As leading providers of ophthalmic care, we are pleased to offer Dropless Cataract Therapy to help our patients eliminate or reduce the number of eye drops required to be administered following cataract surgery. Patients benefit from the affordability and convenience of Dropless Therapy and we have less worries regarding compliance issues and receiving calls from patients and their pharmacies following surgery. Total patient experience remains key to our vision and we are committed to providing the latest skilled care, state-of-the-art technology and innovative therapies to help improve our patients’ vision and their lives.”
Mark L. Baum, CEO of Imprimis, stated, “We welcome Cataract & Laser Institute as a major national account customer. We have several national accounts across the nation now offering our Dropless Therapy and we expect to bring additional important high volume accounts onboard once we register our Texas and new Roxbury, New Jersey pharmacies with the FDA as outsourcing facilities, which are expected to be completed in early to mid-2016. We offer all customers with the convenience and cost-savings of one-stop shopping by providing an array of additional offerings they may require on a daily basis in order to deliver top-quality client care.”
About Imprimis’ Dropless Therapy
Imprimis’ proprietary ophthalmic compounded formulations have been optimized for both injectable and topical applications compatible with the eye. The proprietary drug formulations allow for the increased solubility of a variety of active pharmaceutical ingredients, creating small, uniform particle sizes which enable them to be combined for administration as either an injectable at the time of surgery or used as a topical eye drop post-operatively. Tri-Moxi (triamcinolone acetonide and moxifloxacin hydrochloride) and Tri-Moxi-Vanc (with added vancomycin) are available in single, injectable intraocular doses administered during ocular surgery, where as a result of surgery, there is inflammation and a chance for post-operative infection. Over 400 ophthalmologists are now prescribing Imprimis’ proprietary Dropless Therapy compounded formulations. Since its launch in April 2014, Dropless Therapy formulations have been administered in over 100,000 eye surgeries, primarily cataract surgeries. Ophthalmologists have reported that Dropless Therapy formulations may substantially reduce or eliminate the need for costly eye drops following ocular surgeries, thereby simplifying post-operative patient care and helping to provide safeguards against bacterial infection and inflammation. More information is available at www.GoDropless.com.
About Imprimis Pharmaceuticals
San Diego-based Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a national leader in the development, production and dispensing of novel compounded pharmaceuticals. The company’s business primarily consists of four therapeutic segments including ophthalmology, urology, sinus and integrative medicine. Imprimis dispenses compounded pharmaceuticals in all 50 states from four facilities located in California, Texas, New Jersey and Pennsylvania. For more information about Imprimis, please visit the corporate website at www.ImprimisPharma.com.
All Imprimis compounded formulations may only be prescribed pursuant to a physician prescription for an individually identified patient consistent with federal and state laws governing compounded drug formulations.
SAFE HARBOR
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis’ ability to make commercially available its compounded formulations and technologies in a timely manner, at price points that are attractive to physicians and patients or at all; physician interest in prescribing and patient interest in using its formulations; risks related to its compounding pharmacy operations; its ability to enter into strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis’ filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC’s web site at www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Imprimis Pharmaceuticals Contacts
Investor Contact
Bonnie Ortega
bortega@imprimispharma.com
858.704.4587
Media Contact
Deb Holliday
deb@pascalecommunications.com
412.877.4519
Cataract & Laser Institute Contact
Ronald K. Norlund, DO
rnorlund@cataractandlaserinstitute.net
260.459.8444
Logo - http://photos.prnewswire.com/prnh/20150108/167712LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/imprimis-pharmaceuticals-announces-national-account-agreement-with-the-cataract--laser-institute-300194310.html
SOURCE Imprimis Pharmaceuticals, Inc.; Cataract & Laser Institute
